Duke logo

Genentech GO30140- Solid Tumors - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn what effects, good or bad, atezolizumab has on you and your cancer when combined with bevacizumab and to make sure it is safe.

What is the Condition Being Studied?

Hepatocellular Carcinoma

Who Can Participate in the Study?

Adults who:
- Have advanced or metastatic and/or unresectable hepatocellular carcinoma

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Receive either atezolizumab or atezolizumab and bevacizumab every 3 weeks through a vein in your arm
-- Continue to receive the study drug as long as your doctor thinks it is safe

Study Details

Full Title
An Open-Label, Multicenter Phase Ib Study of the Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00072845
NCT:NCT02715531
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698